SCHEMBL5787713

SCHEMBL5787713

CCC(=CC=Cc1cccc(OC)c1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 1/20 0.52
JUN P05412 1/20 0.52
BCHE P06276 1/20 0.52
MAOB P27338 3/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
RELA Q04206 1/20 0.48
CYP1A2 P05177 3/20 0.47
CYP2D6 P10635 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GRIK1 P39086 1/20 0.46
GRIK2 Q13002 1/20 0.46
ABCG2 Q9UNQ0 2/20 0.46
CYP1A1 P04798 2/20 0.46
CYP1B1 Q16678 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3549405 0.83 ALDH1A1 (0.61) FOSJUNBCHEMAOBALDH1A1
SCHEMBL3544382 0.83 ALDH1A1 (0.61) FOSJUNBCHEMAOBALDH1A1
SCHEMBL3544381 0.83 ALDH1A1 (0.61) FOSJUNBCHEMAOBALDH1A1
SCHEMBL1238378 0.83 THRB (0.53) BCHEMAOBRELACYP3A4
SCHEMBL29964493 0.82 FOS (0.56) FOSJUNBCHEMAOBALDH1A1
SCHEMBL20424923 0.82 FOS (0.56) FOSJUNBCHEMAOBALDH1A1
SCHEMBL10394714 0.81 GRIK1 (0.60) MAOBALDH1A1MEN1KMT2ACYP1A2
SCHEMBL221210 0.81 GRIK1 (0.60) MAOBALDH1A1MEN1KMT2ACYP1A2
SCHEMBL5081017 0.78 ALDH1A1 (0.71) FOSJUNBCHEMAOBALDH1A1
SCHEMBL24352343 0.76 MAPT (0.49) FOSJUNBCHEMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060258722-A1 Condensed ring compound TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258722-A1 Condensed ring compound GPR119, GLP1R, GCGR FOS 1785/4885JUN 2030/4885BCHE 4520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.